📊 KEQU Key Takeaways
Is KEQU a Good Investment? Thesis Analysis
Strong 18% revenue growth is undermined by deteriorating profitability—net income declined 1.5% and diluted EPS fell 40% YoY despite top-line expansion. Thin 3.0% net margin and 5.5% operating margin indicate margin compression from cost pressures, while low ROA of 3.5% suggests capital deployment challenges. The solid balance sheet and positive $10.2M free cash flow provide stability, but the fundamental disconnect between growth and earnings quality warrants cautious positioning.
Why Buy KEQU? Key Strengths
- Strong 18% YoY revenue growth indicating solid market demand in laboratory apparatus sector
- Conservative balance sheet with 0.30x debt-to-equity ratio and robust 10.9x interest coverage ratio
- Healthy liquidity position with 2.12x current ratio and consistent free cash flow generation of $10.2M
KEQU Investment Risks to Consider
- Profitability deterioration despite growth—net income down 1.5% and EPS down 40% YoY signals cost pressures exceeding pricing power
- Dangerously thin margins of 3.0% net and 5.5% operating provide minimal buffer against business disruptions or demand changes
- Very low return ratios (3.5% ROA, 8.8% ROE) indicate inefficient capital deployment and limited shareholder value creation
- Significant EPS decline despite revenue growth suggests either share dilution, operational inefficiency, or unfavorable cost structure
Key Metrics to Watch
- Operating margin trend and gross margin sustainability to identify source of profitability deterioration
- SG&A expenses as percentage of revenue—tracking cost discipline relative to top-line growth
- Free cash flow stability and capital intensity requirements in coming quarters
KEQU Financial Metrics
💡 AI Analyst Insight
The relatively thin 4.8% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.12x current ratio provides a solid financial cushion.
KEQU Profitability Ratios
KEQU vs Default Sector
How KEWAUNEE SCIENTIFIC CORP /DE/ compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is KEQU Overvalued or Undervalued?
Based on fundamental analysis, KEWAUNEE SCIENTIFIC CORP /DE/ has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
KEQU Balance Sheet & Liquidity
KEQU 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: KEWAUNEE SCIENTIFIC CORP /DE/'s revenue has grown significantly by 63% over the 5-year period, indicating strong business expansion. The most recent EPS of $6.38 reflects profitable operations.
KEQU Growth Metrics (YoY)
KEQU Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $67.2M | $692.0K | $0.23 |
| Q2 2026 | $47.8M | $2.2M | $0.82 |
| Q1 2026 | $48.4M | $2.2M | $0.74 |
| Q3 2025 | $46.8M | $1.4M | $0.45 |
| Q2 2025 | $47.8M | $2.2M | $0.93 |
| Q1 2025 | $48.4M | $2.2M | $0.74 |
| Q3 2024 | $46.8M | -$243.0K | $-0.09 |
| Q2 2024 | $50.4M | -$243.0K | $-0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
KEQU Capital Allocation
KEQU SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for KEWAUNEE SCIENTIFIC CORP /DE/ (CIK: 0000055529)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KEQU
What is the AI rating for KEQU?
KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) has an AI rating of HOLD with 55% confidence, based on fundamental analysis of SEC EDGAR filings.
What are KEQU's key strengths?
Claude: Strong 18% YoY revenue growth indicating solid market demand in laboratory apparatus sector. Conservative balance sheet with 0.30x debt-to-equity ratio and robust 10.9x interest coverage ratio.
What are the risks of investing in KEQU?
Claude: Profitability deterioration despite growth—net income down 1.5% and EPS down 40% YoY signals cost pressures exceeding pricing power. Dangerously thin margins of 3.0% net and 5.5% operating provide minimal buffer against business disruptions or demand changes.
What is KEQU's revenue and growth?
KEWAUNEE SCIENTIFIC CORP /DE/ reported revenue of $210.6M.
Does KEQU pay dividends?
KEWAUNEE SCIENTIFIC CORP /DE/ does not currently pay dividends.
Where can I find KEQU SEC filings?
Official SEC filings for KEWAUNEE SCIENTIFIC CORP /DE/ (CIK: 0000055529) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KEQU's EPS?
KEWAUNEE SCIENTIFIC CORP /DE/ has a diluted EPS of $2.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KEQU a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, KEWAUNEE SCIENTIFIC CORP /DE/ has a HOLD rating with 55% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KEQU stock overvalued or undervalued?
Valuation metrics for KEQU: ROE of 8.8% (sector avg: 15%), net margin of 3.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KEQU stock in 2026?
Our dual AI analysis gives KEWAUNEE SCIENTIFIC CORP /DE/ a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KEQU's free cash flow?
KEWAUNEE SCIENTIFIC CORP /DE/'s operating cash flow is $13.2M, with capital expenditures of $3.0M. FCF margin is 4.8%.
How does KEQU compare to other Default stocks?
Vs Default sector averages: Net margin 3.0% (avg: 12%), ROE 8.8% (avg: 15%), current ratio 2.12 (avg: 1.8).